Method Developed for Enriching Trophoblast Population in Samples
|
By LabMedica International staff writers Posted on 02 Sep 2019 |

Image: The transverse section of a chorionic villus (Photo courtesy of Wikimedia Commons).
A recent paper described a technique to increase the proportion of placental trophoblast cells in cervical samples by 700%, which enables individual trophoblasts to be picked out for genetic testing.
Currently, diagnosis of genetic disorders in developing fetuses requires capture of trophoblasts through amniocentesis or chorionic villus sampling, both invasive procedures. Extravillous trophoblasts (EVTs) have the potential to provide the entire fetal genome for prenatal testing. Previous studies have demonstrated the presence of EVTs in the cervical canal and the ability to retrieve a small quantity of these cells by cervical sampling. However, these small quantities of trophoblasts are greatly outnumbered by the population of cervical cells in the sample, making isolation of the trophoblasts difficult.
Investigators at Brown University (Providence, RI, USA) took advantage of differences in morphology between trophoblasts and other cervical cells (trophoblasts are smaller, differ in shape, and have relatively large nuclei) to develop a method to enrich the trophoblast population in a cervical sample through differential settling of the cells in polystyrene wells.
Initially the investigators added small quantities of JEG-3 trophoblast cell line cells into clinical samples from standard Pap tests taken at five to 20 weeks of gestation to determine the optimal workflow. They observed that a four-minute incubation period in the capture wells led to a maximum in JEG-3 cell settling onto the plastic surface with the removal of more than 90% of the cervical cell population, leading to a 700% enrichment in JEG-3 cells.
The investigators then went on to conduct a proof-of-concept study on an imaging and picking platform to demonstrate the ability to pick single trophoblast cells for whole genome amplification. Results showed that the new technique was quick, inexpensive, minimized cell loss, and yielded retrieval of individual trophoblast cells.
"There is a large need for biomedical engineering techniques toward advancing prenatal and women's health," said first author Christina Bailey-Hytholt, a doctoral research student in biomedical engineering at Brown University. "Our work is a step toward more non-invasive prenatal testing options."
The trophoblast enrichment technique was described in the August 20, 2019, online edition of the journal Scientific Reports.
Related Links:
Brown University
Currently, diagnosis of genetic disorders in developing fetuses requires capture of trophoblasts through amniocentesis or chorionic villus sampling, both invasive procedures. Extravillous trophoblasts (EVTs) have the potential to provide the entire fetal genome for prenatal testing. Previous studies have demonstrated the presence of EVTs in the cervical canal and the ability to retrieve a small quantity of these cells by cervical sampling. However, these small quantities of trophoblasts are greatly outnumbered by the population of cervical cells in the sample, making isolation of the trophoblasts difficult.
Investigators at Brown University (Providence, RI, USA) took advantage of differences in morphology between trophoblasts and other cervical cells (trophoblasts are smaller, differ in shape, and have relatively large nuclei) to develop a method to enrich the trophoblast population in a cervical sample through differential settling of the cells in polystyrene wells.
Initially the investigators added small quantities of JEG-3 trophoblast cell line cells into clinical samples from standard Pap tests taken at five to 20 weeks of gestation to determine the optimal workflow. They observed that a four-minute incubation period in the capture wells led to a maximum in JEG-3 cell settling onto the plastic surface with the removal of more than 90% of the cervical cell population, leading to a 700% enrichment in JEG-3 cells.
The investigators then went on to conduct a proof-of-concept study on an imaging and picking platform to demonstrate the ability to pick single trophoblast cells for whole genome amplification. Results showed that the new technique was quick, inexpensive, minimized cell loss, and yielded retrieval of individual trophoblast cells.
"There is a large need for biomedical engineering techniques toward advancing prenatal and women's health," said first author Christina Bailey-Hytholt, a doctoral research student in biomedical engineering at Brown University. "Our work is a step toward more non-invasive prenatal testing options."
The trophoblast enrichment technique was described in the August 20, 2019, online edition of the journal Scientific Reports.
Related Links:
Brown University
Latest BioResearch News
- Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
- Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
- Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
- Single-Cell Method Measures RNA and Proteins to Reveal Immune Responses
- Study Links Midlife Vitamin D to Lower Tau in Alzheimer's
- International Consensus Standardizes Tumor Microbiota Detection and Reporting
- Common Metablolic Enzyme Could Predict Response to Cancer Immunotherapy
- Newly Identfied Genetic Variants in MND Support Prognosis and Family Testing
- Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
- Genetic Cause Identified for Severe Infant Epilepsy
- Study Reveals Diagnostic and Therapeutic Target in Rare Pancreatic Tumors
- Researchers Identify Survival Pathway Undermining Targeted Cancer Drugs
- Large-Scale Study Maps DNA Damage Signatures Across Multiple Cancers
- Study Identifies Distinct Immune Signatures to Early Depression and Psychosis
- Genetic Mutation Behind Aggressive Adult Leukemia Offers Treatment Clues
- Disease Gene Discovery Advances Diagnosis of Rare Movement Disorders
Channels
Clinical Chemistry
view channel
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more
Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy
Routine blood tests that measure low-density lipoprotein (LDL), commonly known as “bad” cholesterol, are widely used to guide lipid-lowering therapy, but they do not always provide a complete picture of... Read more
AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read moreNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read moreMolecular Diagnostics
view channel
Framework Guides Targeted Immunotherapy Selection in Liver Cancer
Primary liver cancer, encompassing hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), is the world’s third-leading cause of cancer-related death, responsible for about 830,000 deaths... Read more
Collaboration Brings Rapid At-Home STI Testing with Virtual Follow-Up
Sexually transmitted infections (STIs) are often asymptomatic, and reliance on clinic-based testing can delay diagnosis and treatment. More than one million curable infections are acquired daily worldwide... Read moreHematology
view channel
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read more
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read moreImmunology
view channel
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read moreMicrobiology
view channel
mNGS CSF Test Identifies CNS Pathogens Missed by Standard Panels
Central nervous system (CNS) infections such as encephalitis, ventriculitis, and brain abscess are among the most time-sensitive diagnostic challenges in neurology. Standard testing can return negative... Read moreRapid Color Test Stratifies Virulent and Resistant Staph Strains
Staphylococcus aureus (golden staph) remains a leading cause of infection-related mortality worldwide, responsible for more than a million deaths each year. Rapidly distinguishing highly virulent or a... Read morePathology
view channel
AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
Reliable prognostic profiling and biomarker screening are essential to guide oncology treatment decisions, while laboratories must balance speed and resource constraints. Earlier identification of high‑risk... Read more
Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer
Cutaneous squamous cell carcinoma (cSCC) is the world’s second most common skin cancer, and while many cases are treatable, a subset becomes highly aggressive and therapy‑resistant. Identifying molecular... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more







